Aspira Women's Health Inc. · OTC:AWHL
Aspira Women's Health — Investor Presentation (September 2024)
30 slides from Aspira Women's Health's investor presentation, Sep 13, 2024
Slide 1: Non-Invasive Tests for the Identification of Gynecologic Disease
Non-Invasive Tests for the Identification of Gynecologic Disease Corporate Presentation September 2024
Slide 2: Safe Harbor
Safe Harbor This presentation contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this presentation are forward-looking statements. These forward-looking statements include, am
Slide 3: Aspira Women's Health Investment Highlights
Aspira Women’s Health Investment Highlights rsx | Revenue Revenue generating commercial diagnostics company focused on products to Company aid in the detection of gynecologic disease of pieay) SHEL Year-over-year volume and revenue growth since 2020 OvaSuite™ (OvaWatch & Ova1Plus) proprietary, Al-po
Slide 4: An Experienced Executive Team
An Experienced Executive Team Nicole Sandford Chief Executive Officer Sandra Milligan, MD, JD President John Kal Michelle Snider Interim Chief Financial P, Commercial Strategy Officer & Operations Deloitte. “PORGANON TORIGEN sema4 & MERCK rogue Health (2) RERERENCE, Genentech == Bactana” Myriad A Me
Slide 5: Our Portfolio of Commercial Products and Pipeline
Our Portfolio of Commercial Products and Pipeline U.S. TAM Ovarian Cancer Patients/Year CvaSuite™ Qya 22040 In Development Marketed C\VaWAT CH 2.0-4.0M — QS Cyawo: 1.24.56 bute Endometriosis Qo 2M Qo. 6.5M r—ti—“‘“‘Cé;™S*~*~é~é«Y UML ‘Copyright (C) Acpra Women's Health ne., 2024 AI Rights Reserved,
Slide 6: Our Suite of Commercial Products
Our Suite of Commercial Products
Slide 7: Historical Clinical Consideration for Women with an Adnexal Mass
Historical Clinical Consideration for Women with an Adnexal Mass > Ko ce Sie we®D Patient presents An internet She visits her Complete While waiting for At the ultrasound with vague search tells her it ObGyn. Physical workup her appointment, appointment, they abdominal could be exam is includes orde
Slide 8: Historical Treatment Paradigm Leads to Negative Outcomes
Historical Treatment Paradigm Leads to Negative Outcomes 1.2M+ women in the US present with an adnexal mass each year, of which 200,000 will be referred for surgery. Most of those surgeries are performed on women without a malignancy. In the US, women with ovarian cancer will wait an average of 24 w
Slide 9: Blood Tests to Understand Malignancy Risk for Every Woman with an Adnexal Mass
Blood Tests to Understand Malignancy Risk for Every Woman with an Adnexal Masses Right Patient. Right Treat CvaSuite” C\vawaTcH Non-Surgical Management For the initial and periodic assessment of risk when an adnexal mass is likely benign or indeterminate in nature Negative Predictive Value (NPV) = 9
Slide 10: OvaSuite Designed to Address a Significant Unmet Need in Gynecologic Care
CvaSuite" Designed to Address a Significant Unmet Need in Gynecologic Care U.S. Total Addressable Market (TAM) Patients/Year May 2024 ne OvawatcH Longitudinal Monitoring The number of patients who benefit from our tests has increased with each expansion of the OvaSuite portfolio. With the launch of
Slide 11: OvaWatch: For Initial and Ongoing Assessment of Ovarian Cancer Risk
i | For Initial and Ongoing Assessment of Ovarian Cancer Risk Ovawatc OvaWatch is a vasive test intended for use in assessing the risk of ovarian cancer for women with adnexal masses that are likely benign or cannot be classified by initial clinical assessment (indeterminate). Cvawate¢H’ With its su
Slide 12: Strong Evidence to Support OvaWatch for Adnexal Mass Management
Strong Evidence to Support OvaWatch for Adnexal Mass Management “Ovarian Cancer Surgical Consideration is Markedly Improved by the Neural Network Powered- MIA3G Multivariate Index Assay” published in Frontiers in Medicine (May 2024) P tromtiors | Use of OvaWatch may have significantly = a reduced su
Slide 13: Ova1Plus: For Women with Adnexal Masses Planned for Surgery
Cai °*| For Women with Adnexal Masses Planned for Surgery Ova1Plus is a proprietary reflex process Ova1 performs better than off-label use of CA-125 alone Included in Guidelines for Adnexal Mass Management Ovarian \ C O G malignancies properly identified (0) by Ovat 59 % i that were missed The Ameri
Slide 14: OvaSuite Market Access and Reimbursement
CvaSuite” | Market Access and Reimbursement We aim to make our OvaSuite of products available to all women "a : 2 G Medicare $8971 ( & Medicaid Available in 9 states Anthem. ae Cigna my v] oo r)) ate ce a Medicare Louisiana “Advantage <HIGHMARK. ga RS agape SNR WwaliCare | guig neces of Texas {12024
Slide 15: Our Development Pipeline
Our Development Pipeline
Slide 16: OvaMDx
(va MDx Aspira’s Advantages Existing protein-based FDA approved test Exclusive rights to miRNA identified by Dana Farber Experience in Al developed tests and proprietary algorithms Brand recognition with healthcare providers Access to large biobank for verification and validation Enhanced Assay for
Slide 17: OvaMDx Development Pathway
CVawox | Development Pathway OvaMDx is an Al-powered multivariate blood test for the identification of ovarian cancer in women diagnosed with an adnexal mass. AWH has an exclusive license for the Dana Farber miRNA technology. Discovery: Complete Verification & Validation Design: In Process Regulator
Slide 18: Endometriosis: A Diagnostic Dilemma
Endometriosis: A Diagnostic Dilemma Endometriosis is a debilitating condition in which tissue similar to the lining of the uterus grows outside the uterus. It affects an estimated 6.5 million women in the US alone. Only 50% of women who undergo a laparoscopic procedure are diagnosed with endometrios
Slide 19: EndoCheck: First-ever Protein-based Assay for Diagnosis of Endometriomas
Qc: First-ever Protein-based Assay for Diagnosis of Endometriomas Aspira’s Advantages EndoCheck Assay Features Designed to aid in the diagnosis of endometriomas, which are present in Y FDA-approved platform approximately 40%+ of women with endometriosis. - Non-invasive, blood-based assay utilizing m
Slide 20: Identification of Endometriomas with an Al-powered Protein Algorithm
Qe Identification of Endometriomas with an Al-powered Protein Algorithm Prediction Values for subsets of Oxford Dataset presented pean ee of te eucome ions pop aialions at Society of Reproductive Investigation (March 2024) USM in he eae x First-of-its-kind blood test with preliminary accuracy of 85%
Slide 21: EndoCheck Development Pathway
@-< Development Pathway EndoCheck is an Al-powered multivariate blood test to aid in the diagnosis of endometrioma, an endometriosis mass located on the ovary Verification & Validation Design: Complete Regulatory & Launch Discovery: Complete Protein signature Verified in three Regulatory strategy pa
Slide 22: EndoMDx: Protein + miRNAs-based Assay for Diagnosis of All Types of Endometriosis
Q. Protein + miRNAs-based Assay for Diagnosis of All Types of Endometriosis Aspira’s Advantages OG Leverages OvaMDx platform development Ty Ongoing clinical study Gf providing samples to complete development GO Al expertise EndoMDx Assay Features EndoMDx is being designed to aid in the diagnosis of
Slide 23: EndoMDx Development Pathway
Dx Development Pathway EndoMDx is an Al-powered multivariate blood test to aid in the diagnosis of all endometriosis Discovery: In Process miRNA and protein candidate features for endometriosis discovered at DFCI under sponsored RD agreement Establish miRNA detection feasibility on BioRad ddPCR Esta
Slide 24: 2024 Product Development Milestones
4 <6 6 O0008000 2024 Product Development Milestones Publication of OvaWatch Longitudinal Monitoring Manuscript and Commercial Launch of Expanded Application Publication of OvaWatch Surgical Selection Manuscript Publication and Presentation of EndoCheck Abstract (with Oxford University) at SRI on 3/1
Slide 25: Operations
Operations
Slide 26: Financial Performance Snapshot
Financial Performance Snapshot Q2 2024 YoY Comparison Product Volume 3% co i Q2 2023 Q2 2024 Product Revenue -2.7% aa Q2 2023 Q2 2024 Gross Margin -480bps Q2 2023 Q2 2024 Sales & Marketing 21% Q2 2023 2 2024 Balance Sheet Adjusted cash as of June 30, 2024: $5.0M* 2024 Operating cash utilization targ
Slide 27: Sales Force Productivity: Doing More with Less
Sales Force Productivity: Doing More with Less Shift to targeted marketing, turn-over of underperforming territories, commercial partnerships and inside sales led to consistent improvement in the number of tests sold by each full-time sales representative. OvaSuite Volume Per Sales Rep* (Field and I
Slide 28: OvaSuite Field and Inside Sales Performance
OvaSuite™ Field and Inside Sales Performance Strategic refresh of commercial capabilities have resulted in steady increases in volume at a lower cost. juarterly Test Volume and Sales & Marketing Expense 7,000 $6.0 2 2 s 2 6,000 $5.0 2 5,000 % 0 ° Higher volume 3 £ 4,000 with much 5 2 lower cost. $ $
Slide 29: 2024 Key Growth Drivers
2024 Key Growth Drivers OvaSuite Adoption and Growth g Market Access and Reimbursement © LAS a Complete commercial refresh to Expand OvaSuite payer adoption and capture the large patient population of improve average unit price women with adnexal masses Accelerate Innovation and R&D Collaboration Op
Slide 30: Contact Us
Contact Us Nicole Sandford Chief Executive Officer investors@aspirawh.com
Aspira Women's Health — Investor Presentation (September 2024) on 6ix